2009
Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial
Abdelmalek M, Sanderson S, Angulo P, Soldevila‐Pico C, Liu C, Peter J, Keach J, Cave M, Chen T, McClain C, Lindor K. Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial. Hepatology 2009, 50: 1818-1826. PMID: 19824078, DOI: 10.1002/hep.23239.Peer-Reviewed Original ResearchConceptsNonalcoholic steatohepatitisBetaine therapyHepatic steatosisAnimal studiesNonalcoholic fatty liver disease activity scoreBiopsy-proven nonalcoholic steatohepatitisRandomized placebo-controlled trialNonalcoholic fatty liver diseaseRandomized placebo-controlled studyPosttreatment liver biopsiesDisease Activity ScorePlacebo-controlled studyPlacebo-controlled trialFatty liver diseaseElevation of insulinNovel therapeutic optionsSecond hit mechanismsOral betaineWilcoxon rank testNASH patientsLiver biopsyActivity scoreLiver diseaseRemethylation of homocysteineSteatosis grade
2006
Familial Aggregation of Insulin Resistance in First-Degree Relatives of Patients With Nonalcoholic Fatty Liver Disease
Abdelmalek M, Liu C, Shuster J, Nelson D, Asal N. Familial Aggregation of Insulin Resistance in First-Degree Relatives of Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology And Hepatology 2006, 4: 1162-1169. PMID: 16901766, DOI: 10.1016/j.cgh.2006.06.001.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseFirst-degree relativesFatty liver diseaseCryptogenic cirrhosisDiabetes mellitusLiver diseaseGenetic predispositionRisk of DMFamilial clusteringFirst-degree family membersBody mass indexInsulin resistance syndromeSignificant survival differenceExpression of IRWarrants further investigationNAFLD patientsMass indexResistance syndromeInsulin resistanceMedical historySurvival differencesHealthy controlsCardiac diseaseRenal stonesFamilial aggregation studies